Sunovion finalizes acquisition of Cynapsus

Sunovion Pharmaceuticals' acquisition of Cynapsus Therapeutics has been finalized through Sunovion's subsidiary Sunovion CNS Development Canada.
The purchase of Cynapsus advances the worldwide strategy laid out by Sunovion, which will see the expansion and diversification of several important therapeutic areas. This includes its neurological portfolio.
Sunovion also plans to develop its clinical development program regarding apomorphine, its novel formulation. Apomorphine was developed to serve as a fast-acting, easily usable, on-demand treatment for OFF episodes that are linked to Parkinson’s disease.
“OFF episodes impair the ability to move and maintain normal activities and are often highly distressing to people with Parkinson’s disease,” Sunovion Chairmain and CEO Nobuhiko Tamura said. “We look forward to the completion of the clinical development program for the sublingual formulation of apomorphine, which, if approved, will be an important treatment option for OFF episodes associated with Parkinson’s disease. Sunovion’s acquisition of Cynapsus reinforces our vision to lead the way to a healthier world and our commitment to patients who are at the center of everything we do.”
Beneficial holders of Cynapsus common shares and purchase warrants will have payments credited to their accounts.